LONGEVITY BIOTECH REPORT 2026 · FREE ACCESS
Longevity biotech is now a $617BN market. See where every dollar comes from.
781 companies to build the most rigorous forecast yet of the longevity drug market — reviewed by experts from Oppenheimer, AstraZeneca, and Einstein.
$617BN
annual revenue by 2045
$30BN+
invested in under 2 years
2035
the year regulation opens
Get instant access — free
Register with a work email to read the Longevity Biotech Report in full.
Free DLT account · No card requiredAlready registered? Log in
SUPPORTED BY
INSIDE THE REPORT
Six questions every biotech strategist is asking. The answers are inside.
$617BN
How do you get to $617BN from where the market is today?
Built on deliberately conservative assumptions — and benchmarked against statins and GLP-1s.
Inside: the four assumptions & diffusion curve
2035
When does the regulatory door open?
Neither FDA nor EMA recognises gerotherapeutics yet. Three independent clocks now point to the same year.
Inside: which three clocks, and the evidence
$230BN
What’s already sitting in today’s pipelines?
A year’s revenue from assets that exist right now, this is the value sitting in today’s pipelines.
Inside: 3,036 assets valued, one by one
Investment/M&A up
Big Pharma: buy or build?
2025 life-sciences M&A was up 81%. The patent cliff is widening every year to 2032.
Inside: the deal map — who’s buying what
50–70%
Is China about to overtake US longevity biotech?
The race is on.
Inside: the 59-company cohort & US response
100x
The highest-conviction investment case in modern economics?
The ROI has never been more compelling
Inside: the full calculation, two ways
“Nobody believed GLP-1s would pass $150 billion… longevity will be the next big move for the pharmaceutical sector.”
Jay Olson, CFA · Managing Director, Biotechnology Equity Research, Oppenheimer & Co
WHO IT’S FOR
Built for the people placing the bets.
Pharma BD & strategy
Know which assets could fill your patent-cliff gap — before your competitors bid on them.
Investors & analysts
See where capital is concentrating, which platforms are de-risked, and when the category re-rates.
Biotech leaders
Benchmark your pipeline against 3,036 valued assets and position for the gerotherapeutic wave.
FOREWORD
“For me, the purpose of longevity medicine is concrete: preserving function, improving recovery and helping people remain independent for longer.”
Dominik Duscher MD PhD · President & CEO, MuseCell Innovations®
REPORT PARTNER
Report supported by MuseCell Innovations. Editorial control rests with Longevity.Technology.
DATA OPERATIONS
Coverage is curated by the Longevity.Technology research team and our 3-stage AI system
Is it really free?
Yes. Create a free DLT account and you get instant access. No card, no trial clock.
What exactly do I get?
The complete report, every chart, and the underlying intelligence on the DLT platform.
We need the asset-level data for our own models.
DLT licenses the full dataset behind this report.